Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

   Completed · Phase 2 · Adult B Acute Lymphoblastic Leukemia

   NCT02997761 · AbbVie Inc. · 1 U.S. investigator

   $15,089research payments

2. [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

   Active, not recruiting · Phase 1 · Prostate Cancer

   NCT06229366 · Eli Lilly and Company · 1 U.S. investigator

   $15,050research payments

3. A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

   Terminated · Phase 1, Phase 2 · Neoplasms

   NCT03648372 · Takeda Pharmaceuticals U.S.A., Inc. · 2 U.S. investigators

   $15,042research payments

4. Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

   Completed · Respiratory Syncytial Virus Infections

   NCT05964582 · Sanofi US Services Inc. · 2 U.S. investigators

   $15,038research payments

5. A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain

   Completed · Phase 2 · Chronic Low-back Pain

   NCT05630196 · Eli Lilly and Company · 1 U.S. investigator

   $15,029research payments

6. A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

   Completed · Phase 3 · Carcinoma, Pancreatic Ductal

   NCT02993731 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

   $15,000research payments

7. Autonomic Reactivity and Personalized Neurostimulation

   Recruiting · Not applicable · Functional Gastrointestinal Disorders (FGIDs)

   NCT06863207 · Neuraxis, Inc. · 0 U.S. investigators

   $15,000research payments

8. Advanta VXT and Flixene PMCF Registry

   Recruiting · Peripheral Arterial Disease

   NCT07161583 · Atrium Medical Corporation · 1 U.S. investigator

   $15,000research payments

9. A Study of Brenipatide in Adult Participants With Schizophrenia

   Recruiting · Phase 2 · Schizophrenia

   NCT07410507 · Eli Lilly and Company · 8 U.S. investigators

   $14,806research payments

10. Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

    Completed · Phase 1 · Parkinson Disease

    NCT05610189 · AbbVie Inc. · 1 U.S. investigator

    $14,700research payments

11. A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

    Completed · Phase 1 · Myelodysplastic Syndromes (MDS)

    NCT02966782 · AbbVie Inc. · 1 U.S. investigator

    $14,672research payments

12. A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

    Completed · Phase 1 · Malignancies

    NCT03236857 · AbbVie Inc. · 1 U.S. investigator

    $14,504research payments

13. A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

    Terminated · Phase 4 · Palmoplantar Psoriasis

    NCT06042920 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $14,129research payments

14. A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

    Recruiting · Phase 3 · Ulcerative Colitis

    NCT07071519 · AbbVie Inc. · 1 U.S. investigator

    $14,042research payments

15. A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

    Completed · Phase 2 · Leukemia, Lymphoid

    NCT04849416 · Eli Lilly and Company · 0 U.S. investigators

    $14,017research payments

16. SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

    Recruiting · Phase 4 · Hemophilia A With Inhibitor

    NCT04647227 · Hema Biologics, LLC · 5 U.S. investigators

    $14,000research payments

17. Mobile Cardiac Outpatient Telemetry for Unexplained Syncope

    Status unknown · Not applicable · Syncope

    NCT05957315 · Philips North America LLC · 1 U.S. investigator

    $14,000research payments

18. Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

    Terminated · Phase 2 · Chronic Graft-versus-host-disease

    NCT03640481 · Sanofi-aventis U.S. LLC · 0 U.S. investigators

    $13,750research payments

19. SpyGlass Surgical Study

    Completed · Pancreatic Diseases

    NCT05822635 · Boston Scientific Corporation · 2 U.S. investigators

    $13,720research payments

20. A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

    Completed · Phase 3 · Colorectal Cancer

    NCT02753127 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

    $13,474research payments

21. CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Terminated · Phase 2 · Squamous Cell Carcinoma of Head and Neck

    NCT04633278 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $13,207research payments

22. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

    Recruiting · Phase 2 · Beta-Thalassemia

    NCT04143724 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $13,150research payments

23. Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

    Terminated · Phase 2 · Solid Tumor

    NCT05023655 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $13,055research payments

24. Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

    Completed · Phase 1 · Bacterial Infections

    NCT02687906 · Melinta Therapeutics, LLC · 3 U.S. investigators

    $13,054research payments

25. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    Recruiting · Phase 3 · Mania

    NCT07140913 · E.r. Squibb & Sons, L.l.c. · 5 U.S. investigators

    $13,009research payments

26. Mucopolysaccharidosis I (MPS I) Registry

    Completed · Mucopolysaccharidosis I (MPS I)

    NCT00144794 · Sanofi US Services Inc. · 13 U.S. investigators

    $12,939research payments

27. A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

    Recruiting · Phase 1, Phase 2 · Spasticity

    NCT04752774 · Ipsen Innovation · 2 U.S. investigators

    $12,805research payments

28. A Study of [14C]-LY3537982 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT05901311 · Eli Lilly and Company · 1 U.S. investigator

    $12,587research payments

29. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

    Completed · Phase 3 · Various Advanced Cancer

    NCT02632409 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $12,545research payments

30. A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruiting · Phase 2 · Head and Neck Squamous Cell Carcinoma (HNSCC)

    NCT06769698 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $12,500research payments

31. Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

    Active, not recruiting · Phase 1 · Advanced Solid Tumors Cancer

    NCT04721015 · AbbVie Inc. · 1 U.S. investigator

    $12,489research payments

32. Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

    Completed · Phase 1, Phase 2 · Human Immunodeficiency Virus

    NCT01734850 · Csl Behring · 2 U.S. investigators

    $12,287research payments

33. Post Market Surveillance Study of the Wingspan Stent System

    Completed · Not applicable · Intracranial Atherosclerosis

    NCT02034058 · Stryker Corporation · 4 U.S. investigators

    $12,067research payments

34. A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

    Terminated · Phase 1 · Leukemia, Myeloid, Acute

    NCT02848001 · Celgene Corporation · 2 U.S. investigators

    $12,054research payments

35. A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

    Completed · Phase 3 · Type 2 Diabetes

    NCT05462756 · Eli Lilly and Company · 3 U.S. investigators

    $11,906research payments

36. Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

    Completed · Bipolar I Disorder

    NCT05956483 · AbbVie Inc. · 3 U.S. investigators

    $11,900research payments

37. Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

    Completed · Phase 1 · Pulmonary Arterial Hypertension

    NCT03950739 · United Therapeutics Corporation · 2 U.S. investigators

    $11,831research payments

38. Investigation of the Ringer Perfusion Balloon Catheter

    Completed · Not applicable · Coronary Artery Perforation

    NCT04849169 · Teleflex LLC · 3 U.S. investigators

    $11,830research payments

39. A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

    Completed · Phase 1 · Malignant Solid Tumor

    NCT03192345 · Sanofi US Services Inc. · 1 U.S. investigator

    $11,716research payments

40. A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

    Withdrawn · Hepatotoxicity

    NCT04635111 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $11,714research payments

41. A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

    Active, not recruiting · Phase 1 · Multiple Sclerosis

    NCT06220201 · E.r. Squibb & Sons, L.l.c. · 10 U.S. investigators

    $11,711research payments

42. A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

    Completed · Phase 3 · Type 1 Diabetes Mellitus

    NCT03740919 · Eli Lilly and Company · 1 U.S. investigator

    $11,632research payments

43. Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

    Completed · Phase 2 · Respiratory Syncytial Virus Infection

    NCT06251024 · Sanofi Pasteur Inc. · 0 U.S. investigators

    $11,500research payments

44. A Study of DF6002 Alone and in Combination With Nivolumab

    Completed · Phase 1 · Solid Tumors

    NCT04423029 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $11,424research payments

45. Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

    Completed · Phase 3 · Epilepsy

    NCT02408549 · UCB Biosciences Inc. · 2 U.S. investigators

    $11,255research payments

46. Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

    Recruiting · Phase 3 · Immune Thrombocytopenia

    NCT07007962 · Sanofi US Services Inc. · 1 U.S. investigator

    $11,250research payments

47. Ultrasound-Guided Erector Spinae Plane Block Following Upper Extremity Surgery

    Withdrawn · Not applicable · Upper Extremity Problem

    NCT04083274 · Ipsen Bioscience Inc. · 1 U.S. investigator

    $11,204research payments

48. A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Recruiting · Phase 3 · Relapsed or Refractory Multiple Myeloma

    NCT05519085 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $11,163research payments

49. A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

    Completed · Phase 3 · Acute Myeloid Leukemia (AML)

    NCT03069352 · AbbVie Inc. · 1 U.S. investigator

    $11,008research payments

50. Clinical Outcomes Study of the Nexel Total Elbow

    Recruiting · Not applicable · Elbow Joint Destruction

    NCT02469662 · Zimmer Biomet Holdings, Inc. · 2 U.S. investigators

    $10,982research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.